What is the recommended oral melatonin dosage for adults, older adults, and children?

Recommended Melatonin Dosages

For adults with chronic insomnia, melatonin is NOT recommended as a treatment based on the highest quality guideline evidence, which found that 2 mg doses showed harms approximately equal to benefits 1. However, when melatonin is used off-guideline or for other indications, specific dosing recommendations exist for different populations.

Adults (General Population)

The American Academy of Sleep Medicine clinical practice guideline explicitly suggests that clinicians NOT use melatonin as a treatment for sleep onset or sleep maintenance insomnia in adults, based on trials using 2 mg doses 1. This is a weak recommendation with very low quality evidence showing harms outweigh benefits.

Despite this guideline recommendation, when melatonin is used in clinical practice:

• Effective doses range from 1-5 mg for general adult populations 2
• Optimal efficacy appears between 2-4 mg/day based on dose-response analysis 3
• The FDA-labeled over-the-counter preparation uses 3 mg tablets 4
• Administration timing: 30-60 minutes before bedtime is standard 2

Important Caveat

The guideline's negative recommendation is based on insomnia treatment specifically. For circadian rhythm disorders or other sleep conditions, melatonin may still have a role, but this falls outside the primary insomnia indication.

Older Adults (≥55 Years)

For older adults, the evidence is more nuanced:

• Melatonin prolonged-release 2 mg is approved in the EU for primary insomnia in patients ≥55 years 5
• Effective doses range from 1-6 mg, with most evidence supporting this range 6
• No clear dose-response relationship has been established in older adults 6
• The prolonged-release formulation administered 1-2 hours before bedtime mimics natural melatonin secretion patterns 5

Key consideration: Melatonin appears most effective in elderly patients who chronically use benzodiazepines or have documented low endogenous melatonin levels during sleep 7. This suggests targeted use rather than universal application.

The prolonged-release formulation showed no tolerance, dependence, rebound insomnia, or withdrawal symptoms in trials up to 6 months 5, addressing a major concern with conventional sleep medications in this age group.

Children and Adolescents

Children with Autism Spectrum Disorder (ASD)

Melatonin is effective and safe for sleep problems in children with ASD, with strong evidence supporting its use 8:

• Starting dose: 1 mg, with escalation protocol 8
• Maximum dose: 4-6 mg depending on response 8
• Timing: 30-60 minutes before bedtime 8
• Escalation strategy: If no response after 2 weeks, increase by 1 mg every 2 weeks up to 6 mg 8

Specific age-based dosing for children with neuropsychiatric conditions:

• Children (general): 0.5-3 mg 2
• Adolescents: 3-5 mg 2
• Optimal dose across pediatric neuropsychiatric populations: 2-4 mg 3
• Optimal timing: 3 hours before bedtime for maximal efficacy 3

Children with Typical Development

Critical warning: A 2025 systematic review found no efficacy data for melatonin use in young children (0-6 years) with typical development 9. Despite this evidence gap, melatonin is the leading cause of unsupervised medication exposure and overdose in emergency departments for this age group 9.

The rise in prescriptions without efficacy data in typically developing children represents a significant safety concern 9.

Children with FASD

For children with fetal alcohol spectrum disorder:

• Melatonin showed significant reductions in sleep onset latency (p = 0.003) 10
• Dosing details not fully specified in the pilot trial, but standard pediatric protocols apply 10

Practical Algorithm for Dosing

Step 1: Determine the indication

• Adult chronic insomnia → Consider alternatives per AASM guidelines 1
• Older adult (≥55 years) with primary insomnia → Consider 2 mg prolonged-release 5
• Child with ASD/neuropsychiatric condition → Start 1 mg, titrate to 2-4 mg 8, 3
• Child with typical development → Avoid use; no efficacy data 9

Step 2: Optimize timing

• Adults: 30-60 minutes before bedtime 2
• Older adults: 1-2 hours before bedtime (prolonged-release) 5
• Children with neuropsychiatric conditions: 3 hours before bedtime for optimal effect 3

Step 3: Duration considerations

• Longer treatment durations associated with increased sleep efficiency and total sleep time in children 3
• Older adults: Safe for up to 6 months without tolerance 5

Common Pitfalls to Avoid

1. Using melatonin as first-line for adult chronic insomnia: The AASM guideline recommends against this 1
2. Prescribing to young children without neurologic conditions: No evidence of efficacy and rising overdose rates 9
3. Inadequate timing: Administration too close to bedtime reduces efficacy, especially in children (use 3 hours before) 3
4. Exceeding 4 mg in most populations: Dose-response curves show maximal efficacy at 2-4 mg 3
5. Ignoring formulation: Prolonged-release may be superior in older adults 5

Safety Profile

Melatonin demonstrates mild side effects at usual doses across all age groups 2. In children with ASD, reported adverse effects included morning sleepiness and loose stools in isolated cases 8. No severe toxicity, dependence, or withdrawal has been documented even at high doses 2.